In Situ Validation of the Endothelial Cell Receptor GRP78 in a Case of Rhinocerebral Mucormycosis

Antimicrob Agents Chemother. 2018 Apr 26;62(5):e00172-18. doi: 10.1128/AAC.00172-18. Print 2018 May.

Evgenii Shumilov¹, Ulrike Bacher^{2

3}, Christina Perske⁴, Alexander Mohr^{5

6}, Helmut Eiffert⁷, Justin Hasenkamp¹, Lorenz Trümper¹, Gerald G Wulf¹, Philipp Ströbel⁴, Ashraf S Ibrahim^{8

9}, Vivek Venkataramani^{10

4}

¹ Department of Hematology and Medical Oncology, University Medicine Göttingen (UMG), Göttingen, Germany.
² Center of Laboratory Medicine (ZLM)/University Institute of Clinical Chemistry, Inselspital, Bern University Hospital, Bern, Switzerland.
³ University Department of Hematology, Inselspital, Bern University Hospital, Bern, Switzerland.
⁴ Department of Pathology, University Medicine Göttingen, Göttingen, Germany.
⁵ Department of Neuroradiology, University Medicine Göttingen, Göttingen, Germany.
⁶ Department of Neuroradiology, University Heidelberg, Heidelberg, Germany.
⁷ Department of Medical Microbiology, University Medicine Göttingen, Göttingen, Germany.
⁸ Los Angeles Biomedical Research Institute at Harbor-University of California Los Angeles (UCLA) Medical Center, Division of Infectious Diseases, Torrance, California, USA ibrahim@labiomed.org ramani@med.uni-goettingen.de.
⁹ David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
¹⁰ Department of Hematology and Medical Oncology, University Medicine Göttingen (UMG), Göttingen, Germany ibrahim@labiomed.org ramani@med.uni-goettingen.de.

No abstract available

Keywords: GRP78; endothelium invasion; glucose-regulated protein; mucormycosis.

Publication types